Abstracts tagged "osteoporosis and treatment"

Abstract Number: 103 • 2013 ACR/ARHP Annual Meeting
Proportion Of U.S. Older Adults Meeting Inclusion Criteria For 2010 ACR Recommendations On Glucocorticoid-Induced Osteoporosis
Robert A. Overman^1,2, Joshua C. Toliver³, Jun-Yen Yeh⁴, Margaret L. Gourlay⁵ and Chad L. Deal⁶, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Rheumatology, Cleveland Clinic, Cleveland, OH, ³Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ⁴Arnold & Marie Schwartz College of Pharmacy and Health Sciences - Divison of Pharmaceutical Sciences, Long Island University, Brooklyn, NY, ⁵Family Medicine, University of North Carolina, Chapel Hill, NC, ⁶Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. Fracture related to GIO increases a patient’s mortality risk and reduces quality of…
Abstract Number: 84 • 2013 ACR/ARHP Annual Meeting
New Formulation With Potential To Prevent and Treat Osteoporosis and Osteoarthritis
A. Torrent¹, E. Montell², J. Vergés¹, P. Dalmau³, R. Ruhí³, M.C. Carceller⁴, A. Blanco⁴, M.C. Terencio⁴, M.L. Ferrándiz⁴ and M.J. Alcaraz⁵, ¹Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain, ²Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain, ³Technological Extraction Dept, BIOIBERICA S.A., Palafolls, Spain, ⁴Department of Pharmacology and IDM, University of Valencia, Burjassot, Spain, ⁵University of Valencia, Burjasot, Valencia, Spain
Background/Purpose: Osteoarthritis (OA) is a multidimensional disease that affects all anatomical joint structures, particularly cartilage, synovium and subchondral bone. In turn, osteoporosis (OP) is a…
Abstract Number: 2354 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Low Bone Mineral Density in Patients with New Onset Giant Cell Arteritis. Do They Get Appropriate Bone Protective Treatment?
Andreas P. Diamantopoulos and Glenn Haugeberg, Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway
Background/Purpose: Giant cell arteritis (GCA) is a common form of vasculitis mainly affecting individuals older than 50 years with a mean onset age of 69…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].